Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.

ABSTRACT:

Introduction

Prior evidence found live attenuated influenza vaccine (LAIV) more effective than inactivated influenza vaccine (IIV) in children aged 2-8 years, leading CDC in 2014 to prefer LAIV use in this group. However, since 2013, LAIV has not proven superior, leading CDC in 2015 to rescind their LAIV preference statement. Here, the cost effectiveness of preferred LAIV use compared with IIV in children aged 2-8 years is estimated.

Methods

A Markov model estimated vaccination strategy cost effectiveness in terms of cost per quality-adjusted life-year gained. Base case assumptions were equal vaccine uptake; IIV use when LAIV was not indicated (in 11.7% of the cohort); and no indirect vaccination effects. Sensitivity analyses included estimates of indirect effects from both

SUBMITTER: Smith KJ 

PROVIDER: S-EPMC4841730 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature